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Background: The methylation inhibitor 5-Aza-2′-deoxycytidine (decitabine, DAC) has a great therapeutic value for
acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). But decitabine monotherapy was associated
with a relatively low rate of complete remission in AML and MDS. We aimed to investigate the effect of several
anti-leukemia drugs in combination with decitabine on the proliferation of myeloid leukemia cells, to select the
most efficient combination group and explore the associated mechanisms of these combination therapies.
Methods: Cell proliferation was tested by MTT assay and CFU-GM assay. Cell apoptosis was evaluated by Annexin V
and PI staining in cell culture, TUNEL assay and transmission electron microscopy in animal study. MicroPET was
used to imaging the tumor in mouse model. Molecular studies were conducted using microarray expression analysis,
which was used to explore associated pathways, and real-time quantitative reverse transcription-PCR, western blot and
immunohistochemistry, used to assess regulation of Wnt/β-catenin pathway. Statistical significance among groups was
determined by one-way ANOVA analysis followed by post hoc Bonferroni’s multiple comparison test.
Results: Among five anti-leukemia agents in combining with decitabine, the sequential combination of decitabine and
idarubicin induced synergistic cell death in U937 cells, and this effect was verified in HEL, SKM-1 cells and AML
cells isolated from AML patients. Importantly, tumor growth inhibition in this sequential combination was found
to be higher than in single agent or controls in vivo. Moreover, sequential combination of the two agents induced
apoptosis and depression of the Wnt/β-catenin pathway in both AML cell culture and animal studies.
Conclusions: The findings demonstrated that sequentially combination of decitabine and idarubicin had synergistic
anti-leukemia effects. These effects were mainly attributed to demethylation of Wnt/β-catenin pathway inhibitors and
downregulation of Wnt/β-catenin pathway nuclear targets.
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5-Aza-2′-deoxycytidine (decitabine, DAC), an analog of
deoxycytidine, contains a nitrogen group substituted for
C-5 of the pyrimidine ring [1]. DNA polymerase facili-
tates the insertion of DAC into DNA during the replica-
tion step of transcription, which upon occurring, leads
to a permanent combination with DNA methyltrans-
ferase (DNMT). By binding DNMT, DAC lowers the
enzyme’s expression levels and bioactivity and causes de-
methylation of hypermethylated DNA, which induces
re-expression of silenced genes [2,3]. As previously re-
ported, low doses of DAC induce epigenetic modulation,
while high doses have cytotoxic effects [4]. Given the
association between DAC-mediated hypomethylation
and reactivation of multiple genes, some groups have
looked to this drug for its important role in the control
of cell proliferation and differentiation [5].
In practice, DAC has been an effective therapy for
acute myeloid leukemia (AML) and myelodysplastic syn-
dromes (MDS). Recently, DAC monotherapy was associ-
ated with a relatively low rate of complete remission
rates in AML and MDS [6-8]. Kantarjianet al. reported
in a phase III randomized study of DAC in treatment of
170 MDS patients, the overall response rate (OR) was
17%, including 9% complete responses [7]. Furthermore,
Issa et al. conducted a Phase I study of 37 patients with
AML receiving DAC in which the OR was 17% [8].
Several groups have attempted to increase the response
rate of DAC-based therapy by developing combinations
treatments [9,10]. By and large, these have taken on three
varieties: combining DAC with other epigenetic modu-
lating agents, cytotoxic agents, and using DAC as a
biologic response modifier to increase the efficacy of
other drugs. Since the effects of these combined therapies
are not ideal, it is necessary to explore novel combinations.
In this study, we have investigated the effect of five
anti-leukemia drugs (idarubicin, IDA; daunorubicin,
DNA; aclarubicin, ACLA; thalidomide, THAL; and homo-
harringtonine, HHT) in combination with DAC, given
either simultaneously or sequentially, on proliferation in
various AML cell lines.Materials and methods
Reagents
DAC was supplied and formulated by Pharmachemie BV,
Haarlem, the Netherlands. HHT was purchased from
Minsheng Pharmacia (Zhejiang, China). IDA and DNR
were purchased from Haizheng Pharmacia (Zhejiang,
China). ACLA was purchased from Wanle Pharmacia
(Shenzhen, China). THAL was purchased from Sigma
(St. Louis, MO, USA). DAC was used immediately after
dissolving it in phosphate buffer saline (PBS). Other
agents were dissolved in PBS and stored at −40°C.AML samples
Bone marrow samples were collected during routine
diagnostic assessment after written informed consent
had been obtained. Patient disease was characterized
using FAB classification, leading to grouping of patient 1
and patient 3 in AML-M5 category with more than 90%
blast cells and patient 2 into AML-M2 category with
80% blast cells; three healthy volunteers were selected
as normal controls. Patients’ mononuclear cells were
separated by Ficoll-Hypaque (Sigma Chemical Co.)
density-gradient centrifugation and used immediately.
All participants provided written informed consent prior
to entering the study. The study conformed to the ethical
guidelines of the 1975 Declaration of Helsinki and was
approved by the Institutional Review Board of the First
Affiliated Hospital of Zhejiang University.
Cell culture
Human AML cell lines, U937 promonocytic human cell
line [11] and HEL erythroleukemia human cell line [12],
were obtained from the Shanghai Cell Culture Institute
(Shanghai, China). SKM-1 was established from a patient
with progression to myelomonocytic leukemia in MDS,
which was defined as refractory leukemia cell line [13].
It was obtained from the Health Science Research
Resources Bank (Osaka, Japan). The cells were grown
in RPMI 1640 plus 10% GIBCO FCS in plastic tissue
culture plates in a humidified atmosphere containing
5% CO2 at 37°C. For the growth inhibition assay, the
leukemic cell lines were cultured at a density of 2 × 105
cells/mL and mononuclear AML cells were cultured at
5 × 105 cells /mL in the medium before treatment.
Cell proliferation assay
Cell proliferation was tested by colorimetric 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazollium bromide
(MTT) assay. MTT (Sigma, USA) was dissolved in PBS
at 5 mg/mL and used to measure cell viability. Briefly,
aliquots (200 μl) of the cell suspension were dispensed
into 96-well flat-bottomed microplates containing vari-
ous chemical dilutions in six replicate rows. The plates
were incubated in a humidified incubator in 5% CO2 for
72 h at 37°C with 20 μl of MTT solution (5 mg/mL
MTT in phosphate-buffered saline (PBS) stored at 4°C).
After the resulting solution was incubated in 5% CO2 for
another 4 h at 37°C, Formazan crystals were dissolved in
200 μl of DMSO. The plates were then analyzed on an
enzyme-linked immunosorbent assay plate reader at
570 nm. All experiments were performed in triplicate.
Colony forming unit granulocyte/macrophage (CFU-GM)
assay
AML cell lines (U937, HEL and SKM-1) were cultured at
different concentrations (5 × 103/mL) in Iscove’s modified
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Paisley, UK) containing 20% fetal bovine serum (FBS)
(Hyclone, Logan, UT, USA), 0.3% agar (Difco, Detroit, MI,
USA) and variable concentrations of either human recom-
binant GM-CSF (Myelogen, from Schering-Plough, Milan,
Italy) or human recombinant IL-3 (gift from Sandoz,
Basel, Switzerland). Negative and positive control cultures
were also established, with recombinant growth factors
replaced by IMDM and 10% supernatant of U937, HEL
and SKM-1, respectively. Colonies with at least 50 cells
were scored after 14 days of culture.
Apoptosis detection by Annexin V and PI staining
Cells were treated with fresh drug preparations and
medium daily for 3 days. Cells were then washed in PBS
and resuspended in 100 μl of binding buffer [10 mm
Hepes/NaOH (pH 7.4), 140 mm NaCl, and 2.5 mm
CaCl2] containing Annexin V 5 μl (BD Pharmingen,
SanDiego, CA, USA). The cells were analyzed by flow
cytometry after the addition of 5 μl propidium iodide (PI).
Annexin V binds to cells that express phosphatidylserine
on the outer layer of the cell membrane, while PI stains
the cellular DNA of those cells with a compromised cell
membrane. This allows for viable cells (unstained with
either fluorochrome) to be distinguished from apoptotic
cells (stained only with Annexin V) and necrotic cells
(stained with both Annexin V and PI).
Methylation-specific polymerase chain reaction
Genomic DNA was prepared from cells and subsequent
bisulfite conversion of genomic DNA was carried out.
The methylation status of the CpG islands in the SFRP1,
DKK3 and HDPR1 gene promoters were determined by
methylation-specific PCR (MSP) as described by Grif-
fiths EA et al. [14]. DNA was amplified according to the
following protocol: 95°C for 5 min, followed by 40 cycles
of 95°C for 1 min, 60°C for 30s, 72°C for 1 min, and a
final extension step of 72°C for 10 min. Amplified prod-
ucts were resolved on 3% agarose gels and visualized
under ultraviolet light after staining with ethidium
bromide. DNA from normal donors was used as nega-








Cyclin D1 ATGTTCGTGGCCTCTAAGATGASssI methylase (New England Biolabs) was used as a posi-
tive control. Results were confirmed by repeat MSP assays
after an independently performed bisulfite treatment.
Real-time quantitative reverse transcription-PCR
Total cellular RNA was isolated from cells using Trizol
(Gibco-BRL). RNA was eluted with RNase-free water,
quantified at an absorbance at 260/280 nm, and used for
reverse transcription reaction. The primer sequences
are present in Table 1. Real-time quantitative reverse
transcription-PCR was performed in an optional 96-well
plate with Bio-Rad iQ5 system (Bio-Rad, USA) and a
commercial SYBR-Green master mix kit (Takara, Japan),
according to the manufacturer’s instruction. Assembled
plates were then covered and run using the following
conditions: an initial denaturation step of 95°C for
10 min followed by 45 cycles at 95°C for 15 s and 60°C
for 1 min. Each sample was measured in triplicate. The
resulting data were analyzed with Bio-Rad iQ5 Optical
System Software version 2.0 and shown as the mean ± SD
of three determinations for each sample.
Western blotting
Cultured cells were collected in lysis buffer (Cell Signal
Technology, Boston, MA, USA). Equal amounts of pro-
teins were separated on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto PVDF membranes (Millipore, Boston,
MA, USA). Membranes were blocked with 5% skim
milk, incubated with primary antibodies at 4°C over-
night in TBS-T (10 mm Tris–HCl, pH 8, 150 mm NaCl,
0.1% Tween 20). The primary antibodies used were as
follows: β-actin, β-catenin, c-Myc, CyclinD1, SFRP1
(Cell Signal Technology), DKK3 and HDPR1 (Abcam,
Cambridge, MA). After incubation with peroxidase-
conjugated secondary antibodies for 2 hours, blots were
revealed by enhanced chemiluminescence procedures
according to the manufacturer’s recommendation.
Microarray expression analysis
The cells with different treatment were collected for total
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74106) following the manufacturer’s instructions. Micro-
array expression assays were performed at the Shanghai-
Bio Corporation (National Engineering Center for Biochip
in Shanghai, China) using the Agilent 4x44K microarrays.
The raw data were normalized using quantile norma-
lization and then analyzed in GeneSpring GX (zcomSili-
con Genetics, Redwood City, CA, USA). Differentially
expressed genes showing a statistical significance (p <
0.05, one way analysis of variance) and ≧3-fold change
between each treatment groups were further analyzed
using SBC analysis system (Biochip, Shanghai, China):
Gene Ontology (GO) analysis was applied to organize
genes into hierarchical categories on the basis of cellular
component, biological process and molecular function;
enrichment pathway analysis (Kegg database) was im-
plemented to uncover the major perturbed pathways.
The microarray gene expression data have been submitted
in NCBI’s Gene Expression Omnibus (GEO, www.ncbi.
nlm.nih.gov/geo/) under accession number GSE54918.
Subcutaneous AML model of NOD/SCID mouse
NOD/SCID mice were purchased from Shanghai labora-
tory animal center. AML cell line, U937 (1×107 cells per
animal), was injected subcutaneously into the right flank
of 6 to 8-week old NOD-SCID mice. When tumors
reached a volume of ~50 mm3, animals were randomly
assigned to one of four groups. The total number of
mice was 16, divided into four groups with 4 each. Ei-
ther DAC (0.5 mg/kg/day) for five consecutive days
followed by a three days of IDA (0.5 mg/kg/day) or DAC
for five days alone and IDA for three days alone. The
untreated control received PBS. Drugs and PBS were
injected intraperitoneally. Tumor volume was measured
and calculated as π/6 length × width2. On Day 7 after
treatment, tumors were evaluated by micro PET. One
mouse from each group was killed according to ethical
animal practice, and tumors were harvested to deter-
mine cell apoptosis expression levels of the Wnt/β-
catenin pathway. All procedures were performed in
accordance with the “Guide for the Care and Use of
Laboratory Animals” published by the National Insti-
tutes of Health (NIH publication 86–23 revised 1985).
Animal protocols were approved by Animal Care and
Facilities Committee of Zhejiang University.
Immunohistochemical staining
Paraffin-embedded tumor tissues from mice were sec-
tioned and deparaffinized with xylene. The slides were
immersed into different concentrations of alcohol (100%,
95%, 75%, 50%, ddH2O) for rehydration and then in 3%
H2O2 to block endogenous peroxidase. For antigen
retrieval, slides were immersed in boiling (95°C −100°C)
citrate buffer (pH 6.0) for 20 min. After washing with PBS,the slides were soaked in blocking solution (3% BSA) at
room temperature for 30 min. The slides were incubated
with primary antibody against β-catenin (Cell Signaling,
Beverly, MA) at 4°C overnight. After rinsing with PBS,
the secondary antibody, HRP Polymer Conjugate Reagent
(SuperPicture Polymer Detection kit), was added for
10 min and DAB Chromogen for 5 min. At each incuba-
tion step, slides were followed with washing in PBS for
5 min. Mayer’s Hematoxylin solution was used for coun-
terstaining. Finally, slides were dehydrated, air-dried and
mounted. For hematoxylin and eosin staining (H&E stain)
sectioned slides were placed in hematoxylin solution for
15 min, washed with ddH2O and then counterstained with
eosin for 5 min.
Measurement of apoptotic cells with TUNEL assay
Cell apoptosis was measured using a TdT–dUTP Ter-
minal Nick-end Labeling (TUNEL) assay and In Situ Cell
Death Detection Kit (Millipore, USA), according to the
manufacturer’s protocol. Briefly, Paraffin-embedded tumor
tissues from mice were sectioned and deparaffinized with
xylene. The slides were immersed into different concentra-
tions of alcohol (100%, 95%, 75%, 50%, ddH2O) for rehy-
dration and then in 3% H2O2 to block endogenous
peroxidase. The slides were then washed using PBS and
incubated for 5 min on ice with permeabilization solution
(0.1% triton X-100 in 0.1% sodium citrate). The cells were
then treated using TUNEL response mixture [450 ml of
label solution (fluorescein–dUTP) and 50 ml of enzyme
solution (TdT)] for 1 h at 37°C in a humid environment.
The label was then incorporated into damaged sites of
DNA. The apoptotic cell was stained brownish–yellow
and observed under light microscopy. TUNEL positive
cells were analyzed with the Image Pro-Plus software.
Transmission electron microscopy
Tumor tissue was prepared for transmission electron mi-
croscopy (TEM) by the standard technical procedures.
Tumor ultrastructure was observed by TEM in Imaging
Facility of Core Facilities, Zhejiang University School of
Medicine, as previously described [15]. Briefly, tumor
sample was fixed in 2.5% glutaraldehyde (4°C, pH 7.4),
postfixed in 1% osmium tetroxide, and embedded in an
epon–araldite mixture. Ultrathin sections of the tumor
tissue were obtained and placed onto mesh copper grids
and stained with uranyl acetate and lead citrate. The cell
microstructure was observed on a Philips Tecnai 10
electron microscope (Philips, Eindhoven, Netherlands).
Cell morphology especially the nuclear and mitochon-
dria were observed.
MicroPET
An R4 micro PET (CTI Concorde Microsystems, LLC)
was used for imaging, and for each mouse in the study,
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vein injection of 3.7–7.4 MBq of 18F-FDG in 200 mL of
PBS, a 7-min prone acquisition scan was performed
approximately 60 min after injection. Mice were main-
tained under isoflurane anesthesia during the injection,
accumulation, and scanning periods. A heating pad, heat
lamp, or hot water was used to dilate the tail veins for
injections. The standardized uptake value (SUV) was
calculated by ASIPro 6.0.5.0 software.
Statistical analysis
Statistical significance among groups was determined by
one-way ANOVA analysis followed by post hoc Bonferroni’s
multiple comparison test. For non-parametric data,
Kruskal-Wallis followed by Dunn’s multiple comparison
test was used. P values less than 0.05 were considered
statistically significant. All data were presented as mean ±
standard deviation (SD). GraphPad PrismV5.0 (GraphPad
Software, San Diego, CA) was used for statistical analysis.
* p < 0.05, ** p < 0.01, ***p < 0.001.
Results
Selection of effective drugs combined with DAC in AML
cell line U937
Individual anti-leukemia drugs (IDA, DNR, ACLA, THAL,
and HHT) were combined with DAC to investigate the
effect of inhibiting proliferation of AML cells. Three
different ways of combining DAC and anti-leukemia drugs
were studied (see Additional file 1: Table S1): simultaneous
combination (group 1) and sequential combination,
separated into two groups (group 2 and group 3) de-
pending on number of times DAC was given. Drug
dosages were selected after calculating IC50 (see Add-
itional file 1: Table S1) using the median-effect method.
For the simultaneous combination group (group 1),
U937 cells were treated with different concentrations of
DAC and anti-leukemia drugs concurrently. In sequen-
tial combination groups, DAC was given to the U937
only once at the first day (group 2) or once a day for the
first two days (group 3), and anti-leukemia drug was
added at the third day. In all combination groups, the
timing for the IC50 of DAC was 72 h. The timing for
the IC50 of the other drugs (HHT, THAL, ACR, DNR,
and IDA) was 72 h in combination group 1, 24 h in
group 2 and 3.
The effects of combinations were estimated using the
CalcuSyn software, which was developed based on the
median-effect method created by Chou et al. [16]. Rep-
resentative experiment was generated from at least 3
independent experiments for each cell line. The CI50 were
reported as mean ± SD (see Additional file 2: Table S3).
After combining DAC with HHT, ACLA, THAL and
DNR both simultaneously and sequentially, the CI values
at the various doses were almost over 0.8. This meantthat no synergistic effect occurred in the combinations.
Moreover, no synergistic effect was also observed in the
simultaneous combination of DAC and IDA. But when
DAC was sequentially combined with IDA, its CI values
on all five doses were under 0.8. The CI values of the
sequential combination with twice given DAC were
lower than the once given DAC (Figure 1). This result
showed that DAC sequentially combined with IDA had
the most notable synergistic effect among the five anti-
leukemia drugs simultaneously or sequentially com-
bined with DAC.
Synergistic effect of sequential combining DAC and IDA
in inhibiting AML cell proliferation
To evaluate the effects of sequentially combining DAC
and IDA on AML cell viability, we treated U937 cells,
other AML cell lines (HEL, SKM-1) and cells from AML
patients using different drug concentrations according to
their IC50 of each compounds (see Additional file 3:
Table S2). The timing for IC50 of DAC was 72 h for
U937, HEL and cells from patients, 96 h for SKM-1. The
timing for IC50 of IDA was 24 h for the three cell lines
and cells from patients. U937 cells were treated with
DAC: 0.2, 0.4, 0.8 and 1.6 μmol/L for 2 days, and se-
quentially with different concentrations of IDA: 20, 40,
80 and 160 nmol/L for 1 day; HEL cells with DAC: 0.02,
0.04, 0.08 and 0.16 μmol/L for 2 days, IDA: 20, 40, 80
and 160 nmol/L for 1 day; SKM-1 cells with DAC: 2, 4,
8 and 16 μmol/L for 3 days; IDA: 4, 8, 16 and 32 nmol/L
for 1 day; AML cells from Patients with DAC: 2, 4, 8
and 16 μmol/L for 2 days; IDA: 50, 100, 200 and
400 nmol/L for 1 day. Since SKM-1 was established
from a patient with progression to myelomonocytic
leukemia in myelodysplastic syndrome (MDS), which
was defined as refractory leukemia [15], it was consid-
ered less sensitive to DAC than other AML cell lines
U937 and HEL. So we treated SKM-1 cells with DAC for
one more day than other cells. Percentages of live/viable
cells in treated plates were measured using MTT prolif-
eration assay and data collected was analyzed by Graph-
Pad Prism.V5.0 software (Figure 2A). The effects of
combinations were estimated using the CalcuSyn soft-
ware. Representative experiment was carried out from at
least 3 independent experiments for each cell line, and
at least twice for cells from AML patients. The CI50
were reported as mean ± SD (see Additional file 2: Table
S3). The sequential combination of DAC and IDA were
synergistic in all studied AML cells, indicated by com-
bination index (CI) values of <0.8 (Figure 2B). The CI
value in U937 cells treated with DAC followed by IDA
ranged from 0.53 to 0.76 (in Hel: 0.40-0.67; in SKM-
1:0.19-0.57; patient 1: 0.35-0.52; Patient 2: 0.42-0.71;
Patient 3: 0.29-0.79), indicating inhibited proliferation of
AML cells achievable by adding DAC before IDA. CFU-
Figure 1 (See legend on next page.)
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Figure 1 CI plots of DAC and anti-leukemia drugs combined effect in human myeloid leukemia cell line U937. The effect of the
combinations was assessed by MTT after 3 day’s culture with drugs. Cells were divided into three groups. The first column, cells treated with DAC
and anti-leukemia drugs simultaneously at the first day. The second column: DAC was added at the first day, anti-leukemia drugs at the third day.
The thirst column: DAC was added at the first and second day, and anti-leukemia drugs at the third day. The effects of combinations were estimated
using the CalcuSyn software, which was developed based on the median-effect method. CI < 0.8 indicates synergy; CI = 0.8 to 1.2 is additive; and
CI > 1.2 means antagonism. The result showed that DAC sequentially combined with IDA had most notable synergistic effect among the five anti-leukemia
drugs simultaneously or sequentially combining with DAC, and sequential combination with twice DAC given were more effective than the once DAC
given when DAC combined with IDA.
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combining DAC and IDA on AML cells by plating
appropriate numbers of AML cells in methylcellulose
medium. The data (Figure 2C) revealed that the number
of AML cell clones was significantly affected when com-
bining DAC and IDA sequentially, as compared to treat-
ment groups using DAC or IDA alone. These results
indicate that the sequential combination of DAC and
IDA has a synergistic effect on the AML cell prolifera-
tion in vitro.Figure 2 Synergistic effect of sequential combining DAC and IDA in i
combining with IDA on cell growth in leukemia cell lines. Cells were treate
1 day. Cell viability was measured by MTT and IC50 was calculated by the m
were analyzed by PrismV5.0 (GraphPad Software, San Diego, CA). Statistical
***p < 0.001. B, CI plots of DAC and IDA sequential combination in human
combinations were present in a fixed molar ratios based on the IC50 value
CalcuSyn software, which was developed based on the median-effect meth
means antagonism. C, AML cell lines U937, HEL and SKM-1 were treated w
of AML cells was evaluated by colony formation assays. Mean ± SD. ***p <Sequential combination of DAC and IDA efficiently inhibits
tumor growth in subcutaneous AML mouse model
In vivo, we designed the control group strictly (Figure 3A),
and observed tumor growth dynamically. Tumor growth
in the combined group versus control group, presented by
tumor growth curve (Figure 3B, mean ± SD), was inhibited
on the day 4 after drug treatment (91 ± 1.9 vs. 189 ±
3.0 mm3, p < 0.01), significantly inhibited on the day 6
(100 ± 2.0 vs. 305 ± 5.9 mm3, p < 0.001), day 8 (150 ± 3.6
vs. 450 ± 8.4 mm3, p < 0.001), day 10 (219 ± 15 vs. 650 ±nhibiting AML cell proliferation. A, Effects of DAC sequentially
d with DAC twice given for 2 days, and then treated with IDA for
edian-effect method. The MTT uptake figures and the effect figures
differences were calculated by one-way ANOVA. *p < 0.05, **p < 0.01,
leukemia cell lines. Cells were treated as previously described. The
s of each drug. The effects of combinations were estimated using the
od. CI < 0.8 indicates synergy; CI = 0.8 to 1.2 is additive; and CI > 1.2
ith DAC, IDA, or DAC combined with IDA, respectively, and the survival
0.001, **p < 0.01, *p < 0.05.
Figure 3 Sequential combination of DAC and IDA efficiently
inhibits tumor growth in subcutaneous AML mouse model. A,
Outlines of the animal experiment protocol. B, Effect of DAC
sequentially combining with IDA on tumor volume in a subcutaneous
AML mouse model transplanted with U937 cells. Tumor volume is
expressed as Mean ± SD. (n = 4). Statistical differences between groups
were analyzed with one-way ANOVA, and statistical significance was
defined as p < 0.05. (*) indicates statistically significant differences
between the combined group and the control group. C, 18F-FDG
micro PET image of subcutaneous AML mouse model treated with
FBS, DAC alone, IDA alone and DAC followed by IDA. The white
arrows point to the area of the subcutaneous AML tumor. The SUV
of control group was 8.25, DAC group was 6.32, IDA group was
7.09, and DAC combining with IDA group was 4.77.
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p < 0.001), day 14 (500 ± 25 vs. 1200 ± 22 mm3, p < 0.001),
and day 16 (800 ± 29 vs. 1500 ± 35 mm3, p < 0.01) after
drug treatment. On the day 18 after drug treatment, the
inhibition effect become decreased (1200 ± 46 vs. 1700 ±
40 mm3, p < 0.05), along with the lengthened time after
drug administration. Meanwhile, the significant inhi-
bition of tumor growth was noted through the tumor
imaging by micro-PET on the day 16 after drug treat-
ment (Figure 3C).
Synergism of sequential combining decitabine and
idarubicin in inducing apoptosis of AML cells and tumor
cells of subcutaneous AML mouse model
To determine whether apoptotic cell death is responsible
for DAC and IDA induced decrease in cell viability, we
performed flow cytometry analysis with Annexin V and
PI staining. AML cells were treated with different
concentrations: U937 with DAC 0.8 nmol/L for 48 h
followed by IDA 40 nmol/L for 24 h, HEL with DAC
0.08 nmol/L for 48 h followed by IDA 40 nmol/L for
24 h, SKM-1 with DAC 8 μmol/L for 72 h followed by
IDA 8 nmol/L for 24 h, according to the concentrations
of each compounds used in the inhibition of AML cells
proliferation. The combinatory effect of DAC and IDA
on AML cell apoptosis was observed, and the results
showed that the apoptosis rates (Annexin V + and PI-)
in the combined group were significantly increased in
the U937, HEL and SKM-1 cell lines compared with the
control, DAC and IDA groups (all p < 0.001, Figure 4A).
Meanwhile, we determined the morphological and ultra-
structural changes in tumor tissue from subcutaneous
AML mouse model by TEM. Compared with the con-
trol, DAC and IDA groups, the tumor cells treated with
DAC followed by IDA showed the obvious apoptosis
characteristics: absence of microvilli on cell membrane,
nuclear and cell membrane blebbing, chromosome
condensation, and the formation of apoptotic bodies
(Figure 4B). We also performed the TUNEL assays to
confirm the apoptosis effect of DAC and IDA sequential
Figure 4 Synergism of sequential combining decitabine and idarubicin in inducing apoptosis of AML cells and tumor cells of
subcutaneous AML mouse model. A, Annexin V and PI staining for apoptosis assay in U937, HEL and SKM-1 cells. Apoptosis was assayed by
Annexin V and PI staining and fluorescence-activated cell sorting analysis. The percentage of apoptotic cells (Annexin V and PI positive) was
indicated in the histogram. B, The Morphological and ultrastructural changes in apoptosis cells. To compare with the control group, DAC group
and IDA group, the tumor cells from subcutaneous AML mouse model treated with DAC followed by IDA some showed the typical characteristic
of apoptosis cells which microvilli on cell membrane were disappeared, bubbles exist on nuclear and cell membrane, chromosome condensation
and the formation of apoptotic bodies. C, TUNEL assay of tumor tissue from subcutaneous AML mouse model confirmed induction of apoptosis
after treatment with DAC alone, IDA alone and DAC followed by IDA. ***p < 0.001, **p < 0.01, *p < 0.05.
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onstrated that the TUNEL-positive cells/hpf in tumor
tissue were remarkably increased in the combination
group versus the other groups (all p < 0.001) (Figure 4C).
These results suggested that the combinational inter-
action between the two drugs significantly inhibited
tumor growth mainly through inducing tumor cells
apoptosis.
Disrupted gene expression profile by sequential
combination of DAC and IDA in AML cells
To gain insights into the mechanism of the combination
effect of DAC and IDA, we used microarray expression
assay to find the differential expression genes between
combination and other three treatment groups (combin-
ation vs. no-treatment control, combination vs. DAC,
combination vs. IDA) (raw data not shown). In order to
find the most sensitive genes to the drugs, we chose a
lower dose than IC50 of each drug. U937 cells were
treated with PBS for 72 h, DAC 0.2 μmol/L for 72 h with
once a day given at the first two days, IDA 20 nmol/L
for 24 h, and DAC 0.2 μmol/L for 48 h with once a day
given at the first two days followed by IDA 20 nmol/L for
24 h. A total of 2294 genes were found to be differentiallyexpressed by at least three-fold between the combination
group and no-treatment control group, 643 genes between
the combination and DAC groups, 1655 genes between
the combination and IDA groups. The differently genes
were processed utilizing GO annotations and pathway
analysis. In enrichment pathway analysis (Kegg), the
differential expression genes between combination and
other three groups are mainly involved in MAPK
signaling pathway, TGF-beta signaling pathway and Wnt
signaling pathway (Table 2). According to the P value and
percent of differential gene expression between different
treatment groups, Wnt pathway was one of the major
perturbed pathways.
Methylation of Wnt antagonists and DNMTs expression in
AML cells
We used the methylation-specific PCR to examine the CpG
methylation status of Wnt antagonists (DKK3, HDPR1,
and SFRP1) in AML cell lines. Various degrees of hyper-
methylation of the gene promoters were observed in
DKK3, HDPR1 and SFRP1 genes in U937, HEL and
SKM-1 cell lines (Figure 5A). The results revealed
complete methylation of DKK3 gene in all the three cell
lines. The promoter of HDPR1 was also completely
Table 2 The major perturbed pathways in combination comparing with other three groups respectively
Groups Pathways Hits Total Percent p value
Combination vs. control (p < 0.001) MAPK signaling pathway 42 271 15.5% 0.0
TGF-beta signaling pathway 17 85 20.0% 0.0
Natural killer cell mediated cytotoxicity 23 141 16.31% 0.0
VEGF signaling pathway 9 76 11.84% 0.0147
Wnt signaling pathway 18 151 11.92% 7.0E-4
Combination vs. DAC (p < 0.05) MAPK signaling pathway 8 271 2.95% 0.0318
p53 signaling pathway 3 69 4.35% 0.0689
TGF-beta signaling pathway 4 85 4.71% 0.0298
Wnt signaling pathway 9 151 5.96% 3.0E-4
Combination vs. IDA (p < 0.05) MAPK signaling pathway 21 271 7.75% 8.0E-4
Natural killer cell mediated cytotoxicity 19 141 13.48% 0.0
p53 signaling pathway 9 69 13.04% 0.0011
PPAR signaling pathway 7 69 10.14% 0.0128
TGF-beta signaling pathway 12 85 14.12% 1.0E-4
Wnt signaling pathway 16 151 10.6% 1.0E-4
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http://www.translational-medicine.com/content/12/1/167methylated in U937 cells but partial methylated in HEL
and SKM-1 cells. SFRP1 was completely methylated in
U937 and SKM-1 cells and partially methylated in HEL
cell. Furthermore, we analyzed DNMT 3A and DNMT3B
protein expression in AML cell lines after 24 h, 48 h
and 72 h of 0.1 μmol/L DAC treatment. In U937 and
SKM-1 cells, western blot analysis showed that DNMT3AFigure 5 Methylation of Wnt antagonists and DNMTs expression in A
primer pairs as described in Methods. M, methylated reaction; U, unmethy
product for the M reaction was 158 bp long and that for the unmethylate
chain reaction. B, Expression of DNMT3A and DNMT3B in AML cell lines. Expre
method in AML cells without treatment as the control group and AML cells wexpression was significantly repressed after treatment with
DAC. Unlike in U937 and SKM-1 cells, DNMT3A expres-
sion was not significantly reduced after treatment with
DAC in HEL cell line, which could be the results of cell-
type specific effect of DAC. Nevertheless, DAC treatment
did not significantly repress DNMT3B in any of the three
AML cell lines tested (Figure 5B).ML cells. A, MSP analysis. MSP was performed using previously published
lated reaction; pos, positive control, neg, negative control. The PCR
d reaction was 165 bp long; MSP, methylation-specific polymerase
ssion of DNMT3A and 3B were assayed by a standard western blot
ith the treatment of DAC for 24 h, 48 h, and 72 h, respectively.
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inhibiting Wnt/β-catenin pathway in AML cells in vitro
and tumor cells from a subcutaneous AML mouse model
RT-PCR and western blot were used to identify the
DNA and protein extracted from the AML cells and
tumor tissue. AML cells were treated with different con-
centrations: U937 with DAC 0.4 nmol/L for 48 h
followed by IDA 40 nmol/L for 24 h, HEL with DAC
0.04 nmol/L for 48 h followed by IDA 40 nmol/L for
24 h, SKM-1 with DAC 4 μmol/L for 72 h followed by
IDA 8 nmol/L for 24 h, according to the concentrations
of each compounds used in the inhibition of AML cells
proliferation. The xenograft mouse models were treatedFigure 6 Effect of sequential combination of DAC and IDA in inhibitin
from a subcutaneous AML mouse model. A, The mRNA expression of in
was measured by RT-PCR in control cultures, DAC treated cultures, IDA trea
HEL and SKM-1 cell lines. Expression was normalized in comparison with co
Statistical differences were calculated by one-way ANOVA. *p < 0.05, **p < 0
inhibitors and downstream genes of Wnt/β-catenin signaling pathway in fo
C, Immunohistochemistry for β-catenin in tumor tissues of subcutaneous A
in group treated with DAC combining with IDA than treated with DAC orwith DAC (0.5 mg/kg/day) for five consecutive days
followed by a three days of IDA (0.5 mg/kg/day). And
control groups were treated with single agent and PBS.
Sequential treatment with DAC followed by IDA signifi-
cantly up-regulated the Wnt antagonist genes (SFRP1,
HDPR1 and DKK3) which resulted in re-expression or
increased expression of these genes both at the mRNA
and protein levels (Figure 6A, 6B). Furthermore, treating
with IDA after DAC caused significantly down-
regulation of the expression of c-Myc, β-catenin and
CyclinD1 genes in AML cells, compared to treatments
with DAC or IDA alone. We also found that the sequen-
tial treatment group induced re-expression or increasedg Wnt/β-catenin pathway in AML cells in vitro and tumor cells
hibitors and downstream genes of Wnt/β-catenin signaling pathway
ted cultures and DAC followed by IDA treated cultures in the U937,
ntrol cultures. The mean ± SD of four different experiments is shown.
.01, ***p < 0.001. B, Western blot analyze the protein expression of
ur cultures of AML cell lines and tumor cells from AML mouse model.
ML mouse model. β-catenin expression was more frequently observed
IDA alone.
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and DKK3) in tumor cells of the subcutaneous AML
mouse. The down-stream genes of Wnt/β-catenin path-
way including β-catenin, c-Myc and CyclinD1 were also
down-regulated, suggesting depression of the Wnt/β-
catenin pathway. Western blot and IHC staining were
used to detect expression of β-catenin in tumor cells of
subcutaneously xenografted AML mice (Figure 6C).
Discussion
DAC is a pyrimidine analogue used to inhibit DNMT.
DNMT inhibition results in anti-leukemic activity are
due to global and gene-specific DNA hypomethylation
that induces re-expression of leukemia-related genes
[17,18]. In the past, the investigators have shown that the
subjects treated with DAC maintain normal hematopoietic
stem cell self-renewal and display terminal differentiation of
acute AML cells, hence its appeal in treating hematopoietic
disorders like leukemia [19-21]. While the rates of
complete remission using DAC are relatively low, how-
ever, hypomethylating-based combinations using DAC
are being investigated to determine if further response rate
improvement in myeloid malignancies can be achieved
without burdening patients with adverse effects. To inves-
tigate the strategy, a number of hypomethylating combin-
ation trials for managing MDS and AML are underway
and include the use of all-trans-retinoic acid (ATRA),
arsenic trioxide (AS2O3), cytarabine (Ara-C) and topo-
isomerase I inhibitors [4,22-24]. Others are considering
the role of combining histone deacetylase (HDAC) inhibi-
tors and Lenalidomide [25,26]. Nevertheless, the most
widely studied combination is that of DAC and HDAC
inhibitors. This combination has been studied in phase I
and early phase II trials in patients with AML and higher
risk MDS, with reported OR ranging from 20 to 50%
[9,10]. Willemze R et al. reported a randomized phase II
study on the effects of DAC combined with IDA in
patients with relapsed acute leukemia in 1993 and 1997, in
which 15 of the 33 (45.5%) patients achieved a complete
remission, higher than the combination of DAC and
amsacrine. But no definite conclusions with respect to effi-
cacy could be drawn as the patient population was quite
small [27,28]. However, there has been no other evidence
confirming whether DAC has a better effect when com-
bined with the first-line anti-leukemia drugs, such as IDA
and DNR. Exploring synergistic combinations and under-
standing the mechanisms underlying these pairings, espe-
cially in situations where DAC and other anti-leukemia
drugs are paired, remains important.
In this study, we investigated five anti-leukemia drugs
(IDA, DNR, ACLA, THAL, and HHT) in combination
with DAC to observe their effect on the growth of
myeloid leukemic cells. The results showed that DAC
sequentially combined with IDA creates a synergisticeffect of inhibiting the proliferation of AML cell lines, as
well as cells from AML patients. Interestingly, the other
anthracyclines including DNR and ACLA did not show
a synergistic effect when combined with DAC. This
suggests a specific biological mechanism resulting in a
concerted effect. IDA is a synthetic analog of DNR and
one of the most effective inhibitors of DNA topoisomer-
ase. Alex et al. found a significant relation between
apoptosis induction in leukemic cells by IDA in vitro
and the disease remission measured by the percent of
residual leukemic cells in bone marrow [29]. In this
study, we found the sequential combination treatment of
DAC and IDA efficiently inhibited the formation of
AML cell clones and tumor growth in a subcutaneous
AML mouse model. Furthermore, DAC sequentially
combined with IDA presented markedly increased effect
in inducing apoptosis of AML cells cultured in vitro and
the tumor cells from the mouse model. We presume
that the effect of DAC sequentially combined with IDA
is mediated through apoptosis and inhibition of prolifer-
ation of cultured leukemic cells and tumor growth in a
subcutaneous AML mouse model.
The temporal dependence of the combined treatments
was also investigated, by testing the efficacy of DAC and
IDA given simultaneously, DAC given once followed by
IDA, and DAC given two or three times followed by
IDA. We found that DAC added for two or more times
followed by IDA resulted in the most synergistic activity
when compared to the other treatment methods. A
Phase I clinical trial of DAC prior to standard induction
chemotherapy for patients with AML also demonstrated
that demethylation of genes treated with DAC prior to
chemotherapy might play a crucial role in enhancing the
anti-leukemia effect [30], indicating that sequentially
combining DAC with anti-leukemia drugs might be a
better strategy for the design of a clinical trial. In our
study, treating with DAC prior to IDA presented a syn-
ergistic effect in the AML cells. And this combination
regimen significantly inhibited the tumor growth and
induced apoptosis in a xenograft mouse model. These
results suggested that DAC sequentially combined with
IDA could enhance the anti-leukemia effect both in vitro
and in vivo.
There are several molecular mechanisms and cell
signaling pathways involved in tumor cell proliferation
and apoptosis. In searching for the mechanism of syn-
ergy, we used microarray expression analysis to explore
the associated pathways. Our results showed that the
Wnt pathway was one of the most significantly per-
turbed pathways. It has been reported that the canonical
Wnt pathway-Wnt/β-catenin signaling plays an important
role in survival, proliferation and differentiation of
hematopoietic stem cells, which ultimately contributes
to the pathogenesis of leukemia [31-33]. The Wnt/β-
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http://www.translational-medicine.com/content/12/1/167catenin signaling pathway is an important target in several
leukemogenic pathways supporting self-renewal, apoptosis-
induction and proliferation of AML cells [34]. Different
molecular mechanisms have been implicated in the
abnormal activation of the Wnt/β-catenin signaling.
Activation of Wnt/β-catenin signaling leads to inhib-
ition of GSK-3β activity, resulting in accumulation of
cytoplasmic β-catenin. This protein then becomes
available to bind the TCF/LEF family of transcription
factors and subsequently induces target proteins ex-
pression including c-Myc and cyclin D1 [33,35,36]. It
has also been reported that Wnt/β-catenin signaling re-
gulates c-Myc–mediated apoptosis, cytochrome c and
caspase activation. Cyclin D1 is a key regulator of cell fate,
such as cellular senescence, apoptosis, proliferation and
tumorigenesis. The activation of the Wnt/β-catenin path-
way due to the loss of its antagonists is associated with
gene promoter hypermethylation, which may be involved
in the pathogenesis and prognosis of leukemia [37].
RT-PCR, western blot, and IHC staining were used to
demonstrate the changes involved in the Wnt/β-catenin
pathway. β-catenin and downstream genes, c-Myc and
cyclinD1, were downregulated in AML cells both in vivo
and in vitro when treated with the sequential combin-
ation of DAC and IDA compared with DAC and IDA
alone. Moreover, Wnt antagonists SFRP1, HDPR1 and
DKK3 were methylated in three AML cell lines. Treat-
ment with DAC allows for the re-expression of Wnt
antagonists. However, DAC followed by IDA induces
even further increased expression of Wnt antagonists
compared to DAC alone. It is also clear that DAC upre-
gulates the expression of various tumor inhibitors by
way of demethylation of the gene promoter, resulting in
inhibition of cell proliferation [38]. In this study, we
found few changes in Wnt antagonist expression levels
in the AML cells treated with IDA alone. However,
combined treatment resulted in a significant increase in
expression levels of these antagonists. This indicates that
upregulation of Wnt antagonists and downregulation of
Wnt downstream genes enhances an anti-leukemia effect
and may partially explain the mechanism behind the
combined effect of DAC and IDA.
Conclusion
We concluded that DAC sequentially combined with
IDA has a synergistic anti-leukemia effect in vitro and
significant effect on tumor volume reduction and apop-
tosis induction in a xenograft mouse model. The up-
regulation of Wnt antagonists and subsequent inhibition
of Wnt/β-catenin signaling with the two drugs in com-
bination may explain this effect. These findings suggest
clinical potential in sequential administration of DAC
and IDA in the treatment of myeloid leukemia and high-
risk MDS.Additional files
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